BIOMAT Database Logo BIOMAT Database Logo

Ifosfamide/mesna and hematuria. 1987

C B Pratt, and M P Goren

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D007223 Infant A child between 1 and 23 months of age. Infants
D008623 Mercaptoethanol A water-soluble thiol derived from hydrogen sulfide and ethanol. It is used as a reducing agent for disulfide bonds and to protect sulfhydryl groups from oxidation. 2-ME,2-Mercaptoethanol,2 Mercaptoethanol
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006417 Hematuria Presence of blood in the urine. Hematurias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

C B Pratt, and M P Goren
Ifosfamide and mesna.
November 1989, The Medical letter on drugs and therapeutics,
C B Pratt, and M P Goren
Ifosfamide and mesna.
March 1990, Clinical pharmacy,
C B Pratt, and M P Goren
Ifosfamide/mesna encephalopathy.
April 1987, Lancet (London, England),
C B Pratt, and M P Goren
Ifosfamide, mesna, and encephalopathy.
June 1985, Lancet (London, England),
C B Pratt, and M P Goren
Avoiding ifosfamide/mesna encephalopathy.
August 1986, Lancet (London, England),
C B Pratt, and M P Goren
Ifosfamide/mesna nomogram and serum albumin.
October 1986, Lancet (London, England),
C B Pratt, and M P Goren
Ifosfamide/mesna nomogram and serum albumin.
November 1986, Lancet (London, England),
C B Pratt, and M P Goren
Ifosfamide and Mesna in advanced malignancies.
March 1988, Chinese medical journal,
C B Pratt, and M P Goren
Ifosfamide, mesna, and nephrotoxicity in children.
January 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
C B Pratt, and M P Goren
Fatal encephalopathy with ifosfamide/mesna.
January 1989, Pediatric hematology and oncology,
Copied contents to your clipboard!